This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 892-895, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.892-895.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain

Carmen Betriu,1* Iciar Rodríguez-Avial,1 Blas Ali Sánchez,1 María Gómez,1 Juan Álvarez,2 Juan J. Picazo, and Spanish Group of Tigecycline{dagger}

Department of Clinical Microbiology, Hospital Clínico San Carlos,1 Scientific Department, Wyeth Farma, Madrid, Spain2

Received 3 August 2001/ Returned for modification 15 October 2001/ Accepted 3 December 2001

The antimicrobial activities of tigecycline (GAR-936) were compared with those of other agents against 1,087 strains recently isolated in 12 Spanish medical centers. Tigecycline showed activity against a wide spectrum of aerobic and anaerobic bacteria, including strains such as methicillin-resistant Staphylococcus aureus, coagulase-negative staphylococci, penicillin-resistant Streptococcus pneumoniae, Enterococcus faecium, Acinetobacter baumannii, and Stenotrophomonas maltophilia.

* Corresponding author. Mailing address: Department of Clinical Microbiology, Hospital Clínico San Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain. Phone: 34913303485. Fax: 34913303478. E-mail: cbetriu{at}efd.net.

{dagger} Members of the Spanish Group of Tigecycline are listed in the Appendix.

Antimicrobial Agents and Chemotherapy, March 2002, p. 892-895, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.892-895.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Reinert, R. R., Low, D. E., Rossi, F., Zhang, X., Wattal, C., Dowzicky, M. J. (2007). Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60: 1018-1029 [Abstract] [Full Text]  
  • Izdebski, R., Sadowy, E., Fiett, J., Grzesiowski, P., Gniadkowski, M., Hryniewicz, W. (2007). Clonal Diversity and Resistance Mechanisms in Tetracycline-Nonsusceptible Streptococcus pneumoniae Isolates in Poland. Antimicrob. Agents Chemother. 51: 1155-1163 [Abstract] [Full Text]  
  • Lolans, K., Rice, T. W., Munoz-Price, L. S., Quinn, J. P. (2006). Multicity Outbreak of Carbapenem-Resistant Acinetobacter baumannii Isolates Producing the Carbapenemase OXA-40.. Antimicrob. Agents Chemother. 50: 2941-2945 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Gomez, M., Rodriguez-Avial, I., Picazo, J. J. (2005). In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 56: 349-352 [Abstract] [Full Text]  
  • Sun, H. K., Ong, C. T., Umer, A., Harper, D., Troy, S., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations. Antimicrob. Agents Chemother. 49: 1629-1632 [Abstract] [Full Text]  
  • Muralidharan, G., Fruncillo, R. J., Micalizzi, M., Raible, D. G., Troy, S. M. (2005). Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects. Antimicrob. Agents Chemother. 49: 1656-1659 [Abstract] [Full Text]  
  • Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., Troy, S. (2005). Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects. Antimicrob. Agents Chemother. 49: 220-229 [Abstract] [Full Text]  
  • Pachon-Ibanez, M. E., Jimenez-Mejias, M. E., Pichardo, C., Llanos, A. C., Pachon, J. (2004). Activity of Tigecycline (GAR-936) against Acinetobacter baumannii Strains, Including Those Resistant to Imipenem. Antimicrob. Agents Chemother. 48: 4479-4481 [Abstract] [Full Text]  
  • Jacobus, N. V., McDermott, L. A., Ruthazer, R., Snydman, D. R. (2004). In Vitro Activities of Tigecycline against the Bacteroides fragilis Group. Antimicrob. Agents Chemother. 48: 1034-1036 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Rodriguez-Avial, I., Gomez, M., Sanchez, B. A., Picazo, J. J. (2004). In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of Macrolide and Tetracycline Resistance. Antimicrob. Agents Chemother. 48: 323-325 [Abstract] [Full Text]  
  • Kitzis, M. D., Ly, A., Goldstein, F. W. (2004). In Vitro Activities of Tigecycline (GAR-936) against Multidrug-Resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 366-367 [Full Text]  
  • Cercenado, E., Cercenado, S., Bouza, E. (2003). In Vitro Activities of Tigecycline (GAR-936) and 12 Other Antimicrobial Agents against 90 Eikenella corrodens Clinical Isolates. Antimicrob. Agents Chemother. 47: 2644-2645 [Abstract] [Full Text]  
  • Hsueh, P.-R., Teng, L.-J., Lee, C.-M., Huang, W.-K., Wu, T.-L., Wan, J.-H., Yang, D., Shyr, J.-M., Chuang, Y.-C., Yan, J.-J., Lu, J.-J., Wu, J.-J., Ko, W.-C., Chang, F.-Y., Yang, Y.-C., Lau, Y.-J., Liu, Y.-C., Leu, H.-S., Liu, C.-Y., Luh, K.-T. (2003). Telithromycin and Quinupristin-Dalfopristin Resistance in Clinical Isolates of Streptococcus pyogenes: SMART Program 2001 Data. Antimicrob. Agents Chemother. 47: 2152-2157 [Abstract] [Full Text]  
  • Cercenado, E., Cercenado, S., Gomez, J. A., Bouza, E. (2003). In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 52: 138-139 [Full Text]  
  • Milatovic, D., Schmitz, F.-J., Verhoef, J., Fluit, A. C. (2003). Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates. Antimicrob. Agents Chemother. 47: 400-404 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»